[go: up one dir, main page]

ZA200904704B - Treatment of cachexia - Google Patents

Treatment of cachexia

Info

Publication number
ZA200904704B
ZA200904704B ZA200904704A ZA200904704A ZA200904704B ZA 200904704 B ZA200904704 B ZA 200904704B ZA 200904704 A ZA200904704 A ZA 200904704A ZA 200904704 A ZA200904704 A ZA 200904704A ZA 200904704 B ZA200904704 B ZA 200904704B
Authority
ZA
South Africa
Prior art keywords
cachexia
treatment
prevention
receptors
tertatolol
Prior art date
Application number
ZA200904704A
Other languages
English (en)
Inventor
David Cavalla
Original Assignee
Myotec Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myotec Therapeutics Ltd filed Critical Myotec Therapeutics Ltd
Publication of ZA200904704B publication Critical patent/ZA200904704B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
ZA200904704A 2006-12-05 2009-07-03 Treatment of cachexia ZA200904704B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0624282.0A GB0624282D0 (en) 2006-12-05 2006-12-05 Treatment of cachexia

Publications (1)

Publication Number Publication Date
ZA200904704B true ZA200904704B (en) 2010-05-26

Family

ID=37671884

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904704A ZA200904704B (en) 2006-12-05 2009-07-03 Treatment of cachexia

Country Status (16)

Country Link
US (1) US8716325B2 (xx)
EP (2) EP2094254B1 (xx)
JP (1) JP5166437B2 (xx)
CN (1) CN101610760B (xx)
AT (1) ATE513543T1 (xx)
AU (1) AU2007330607B2 (xx)
BR (1) BRPI0720114A8 (xx)
CA (1) CA2671622C (xx)
DK (1) DK2094254T3 (xx)
ES (1) ES2395244T3 (xx)
GB (1) GB0624282D0 (xx)
PL (1) PL2094254T3 (xx)
PT (1) PT2094254E (xx)
RU (1) RU2485950C2 (xx)
WO (1) WO2008068477A1 (xx)
ZA (1) ZA200904704B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907350D0 (en) * 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
WO2014016585A1 (en) * 2012-07-25 2014-01-30 Psioxus Therapeutics Limited Use of s-pindolol for treating cachexia and sarcopenia
CN110169962B (zh) * 2013-03-14 2023-02-03 艾可迪迈治疗有限公司 用于治疗癌症的氧烯洛尔组合物
CA3015313A1 (en) 2016-02-26 2017-08-31 Actimed Therapeutics Ltd S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
GB2593902B (en) * 2020-04-07 2022-04-13 Actimed Therapeutics Ltd Salt of a pharmaceutical compound
GB202114564D0 (en) 2021-10-12 2021-11-24 Actimed Therapeutics Ltd Oral formulation
WO2025219590A1 (en) 2024-04-19 2025-10-23 Actimed Therapeutics Ltd Beta-blockers for preserving muscle mass, bone density, and cardiac function in weight loss treatments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US6545040B1 (en) 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
CA2025398A1 (en) 1989-09-20 1992-03-15 Timothy Gerard Dinan Diagnosis and treatment of a disorder of the gastrointestinal tract
US5120791A (en) 1990-07-27 1992-06-09 Lisco, Inc. Golf ball cover compositions
WO2000021509A2 (en) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
KR20020072299A (ko) 2000-01-31 2002-09-14 화이자 프로덕츠 인코포레이티드 Ｐｄｅ4 이소자임의 선택적 억제제로서 유용한니코틴아미드 벤조접합된-헤테로사이클릴 유도체
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
US6855729B2 (en) 2001-02-20 2005-02-15 Timothy G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
EP1793818A2 (en) 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1865779A4 (en) 2005-03-21 2008-06-04 Vicus Therapeutics Spe 1 Llc COMPOSITIONS AND METHODS FOR ENHANCING CACHEXIA
EP1991270A4 (en) 2005-12-22 2009-12-02 Anaborex Inc COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CACHEXIA
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AR063627A1 (es) 2006-11-09 2009-02-04 Boehringer Ingelheim Int Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
EP2155180B1 (en) 2007-04-24 2016-07-13 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
EP2259844A4 (en) 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES

Also Published As

Publication number Publication date
PT2094254E (pt) 2011-09-19
BRPI0720114A2 (pt) 2014-04-15
US8716325B2 (en) 2014-05-06
RU2485950C2 (ru) 2013-06-27
CN101610760B (zh) 2012-09-26
CN101610760A (zh) 2009-12-23
EP2359822A1 (en) 2011-08-24
CA2671622C (en) 2015-01-27
CA2671622A1 (en) 2008-06-12
EP2094254B1 (en) 2011-06-22
JP2010511685A (ja) 2010-04-15
WO2008068477A1 (en) 2008-06-12
AU2007330607A1 (en) 2008-06-12
EP2359822B1 (en) 2016-08-03
ES2395244T3 (es) 2013-02-11
GB0624282D0 (en) 2007-01-10
PL2094254T3 (pl) 2011-12-30
EP2094254A1 (en) 2009-09-02
BRPI0720114A8 (pt) 2016-01-19
DK2094254T3 (da) 2011-10-03
AU2007330607B2 (en) 2013-02-07
ATE513543T1 (de) 2011-07-15
RU2009125548A (ru) 2011-01-20
JP5166437B2 (ja) 2013-03-21
US20100292270A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
ZA200904704B (en) Treatment of cachexia
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
NO20091260L (no) Kombinasjonsbehandling for diabetes mellitus
GT200600046A (es) Terapia de combinacion
PL1979355T3 (pl) Pochodne spiro imidazoli jako modulatory PPAR
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
TNSN08284A1 (en) Masking the taste of powders
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
WO2008075201A3 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2007075825A3 (en) Lipophilic anticancer drug compounds
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
WO2008087329A3 (fr) Nouveau médicament pour le traitement d'un cancer gastrique
WO2007104933A8 (en) Chemical compounds
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
WO2007011958A3 (en) Intraoral dosage forms of glucagon
WO2006089218A3 (en) Methods and compositions for modulating angiogenesis